MIGAL Galilee Research Institute
MIGAL is an internationally-recognized multi-disciplinary applied research institute in Israel, specializing in biotechnology, computer sciences, plant science, agriculture, environmental sciences, food, nutrition, and health. It is developing an oral Coronavirus vaccine, leveraging its extensive experience in vaccine development, including a successful project against avian coronavirus, to rapidly create a human vaccine for COVID-19. The institute collaborates with industry leaders and has a large team of PhDs and researchers.
Industries
Nr. of Employees
large (251-1000)
MIGAL Galilee Research Institute
Patents
Products
Oral coronavirus subunit vaccine candidate (preclinical)
A preclinical oral subunit vaccine candidate composed of engineered chimeric proteins based on coronavirus S and N domains, formulated for mucosal delivery and produced via microbial expression and fermentation processes.
Oral coronavirus subunit vaccine candidate (preclinical)
A preclinical oral subunit vaccine candidate composed of engineered chimeric proteins based on coronavirus S and N domains, formulated for mucosal delivery and produced via microbial expression and fermentation processes.
Services
Design and execution of preclinical studies assessing safety, immunogenicity and protection in animal models for vaccine candidates.
Development of fermentation media and scalable processes for recombinant protein production with alignment to pharmaceutical regulations and GMP standards.
Computational chemistry and bioinformatics services to identify and optimize antigen structural motifs and design chimeric constructs for mucosal immunogenicity.
Execution of licensing agreements and transfer of vaccine development technology to commercial entities for further development and commercialization.
Design and execution of preclinical studies assessing safety, immunogenicity and protection in animal models for vaccine candidates.
Development of fermentation media and scalable processes for recombinant protein production with alignment to pharmaceutical regulations and GMP standards.
Computational chemistry and bioinformatics services to identify and optimize antigen structural motifs and design chimeric constructs for mucosal immunogenicity.
Execution of licensing agreements and transfer of vaccine development technology to commercial entities for further development and commercialization.
Expertise Areas
- Vaccine development (subunit and mucosal vaccines)
- Mucosal immunology and antigen delivery
- Protein engineering and recombinant expression
- Fermentation and GMP process development
Key Technologies
- Oral mucosal vaccination platforms
- Subunit vaccine antigen design (S and N proteins)
- Chimeric protein engineering
- E. coli recombinant expression and secretion systems